Trials / Completed
CompletedNCT04121260
A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma
A Phase 1, Open-label, Multicenter Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Chinese Subjects With Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and pharmacokinetic of Daratumumab subcutaneously in Chinese participants with relapsed or refractory Multiple Myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Daratumumab | Participants will receive dose 1 daratumumab with 30,000 U (2000 U/mL) with rHuPH20 SC injection. |
Timeline
- Start date
- 2019-12-25
- Primary completion
- 2021-04-27
- Completion
- 2023-10-13
- First posted
- 2019-10-09
- Last updated
- 2023-12-08
Locations
5 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04121260. Inclusion in this directory is not an endorsement.